Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Market Cap	2.88B
Revenue (ttm)	184.91M
Net Income (ttm)	-70.14M
Shares Out	95.95M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	281,081
Average Volume	424,368
Open	29.30
Previous Close	30.05
Day's Range	29.30 - 30.80
52-Week Range	19.80 - 33.65
Beta	-0.19
RSI	62.82
Earnings Date	Nov 14, 2025

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company’s products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 34
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6704

Financial Performance

In 2024, TPEX:6704's revenue was 170.03 million, an increase of 20.44% compared to the previous year's 141.18 million. Losses were -83.32 million, -5.41% less than in 2023.